Trial Profile

A Phase I/Randomized Phase II Study of Cediranib (NSC 732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Cisplatin; Pemetrexed
Indications Malignant-mesothelioma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Apr 2025 Planned End Date changed from 7 Mar 2025 to 19 Mar 2026.
05 Jun 2018 Primary endpoint (Progression-free survival (Phase II)) has been met, according to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com